Recent Advancements of Nanomedicine in Neurodegenerative Disorders Theranostics
The DOI matches its Crossref record; 373 of the 373 references it cites were found in a registry or an index.
Abstract
Recent times have witnessed an upsurge in the incidence of neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, Huntington's disease, Prion disease, and amyotrophic lateral sclerosis. The treatment of the same remains a daunting challenge due to the limited access of therapeutic moieties across the blood–brain barrier. Engineered nanoparticles with a size less than 100 nm provide multifunctional abilities for solving these biomedical and pharmacological issues due to their unique physico‐chemical properties along with capability to cross the blood–brain barrier. Needless to mention, there is a scarcity of review articles summarizing recent developments of various nanomaterials including liposomes, polymeric nanoparticles, metal nanoparticles, and bio‐nanoparticles toward the therapeutic and theranostics applications for various neurodegenerative disorders. Here, a broad spectrum of nanomedicinal approaches to eradicate neurodegenerative disorders is provided, along with a brief account of neuroprotection and neuronal tissue regeneration, current clinical status, issues related to safety, toxicity, challenges, and future outlook.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Using nanocarriers like liposomes, nanoparticles, and micelles, radiopharmaceuticals can be protected, ensuring their delicate contents remain intact, while also offering improved compatibility and extended circulation within the body [63].”
From Radiopharmaceuticals: navigating the frontier of precision medicine and therapeutic innovation (2024) · cites this paper as [63]
In the citing paper
“Owing to their unique physicochemical properties and inherent ability to penetrate the BBB, engineered NPs with dimensions below 100 nm show considerable promise in addressing a range of biological and pharmacological challenges [65].”
From Targeted Nanoparticles for Drug Delivery Across the Blood–Brain Barrier in Early and Late Stages of Alzheimer's Disease: A Review (2026) · cites this paper as [65]
Citations
Cites
Mitochondrial Dysfunction and Oxidative Stress in Neurodegenerative Diseases
Lin, M. T., & Beal, M. F. (2006) · Nature · doi:10.1038/nature05292 · Cited by 6,455
ILAE official report: a practical clinical definition of epilepsy
Fisher, R. S., Acevedo, C., Arzimanoglou, A., Bogacz, A., Cross, J. H., Elger, C. E., Engel, J., Forsgren, L., French, J. A., Glynn, M., et al. (2014) · Epilepsia · doi:10.1111/epi.12550 · Cited by 6,108
Poewe, W., Seppi, K., Tanner, C. M., Halliday, G. M., Brundin, P., Volkmann, J., Schrag, A.-E., & Lang, A. E. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.13 · Cited by 5,415
Uttara, B., Singh, A., Zamboni, P., & Mahajan, R. (2009) · Current Neuropharmacology · doi:10.2174/157015909787602823 · Cited by 3,378
Ageing as a risk factor for neurodegenerative disease
Hou, Y., Dan, X., Babbar, M., Wei, Y., Hasselbalch, S. G., Croteau, D. L., & Bohr, V. A. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0244-7 · Cited by 3,310
Genomic classification of cutaneous melanoma
Akbani, R., Akdemir, K. C., Aksoy, B. A., Albert, M., Ally, A., Amin, S. B., Arachchi, H., Arora, A., Auman, J. T., Ayala, B., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.044 · Cited by 3,151
Blood–brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders
Sweeney, M. D., Sagare, A. P., & Zlokovic, B. V. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.188 · Cited by 3,076
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
Adams, D., Gonzalez-Duarte, A., O’Riordan, W. D., Yang, C.-C., Ueda, M., Kristen, A. V., Tournev, I., Schmidt, H. H., Coelho, T., Berk, J. L., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716153 · Cited by 3,047
Alzheimer Disease Genetics Consortium (ADGC), Kunkle, B. W., The European Alzheimer’s Disease Initiative (EADI), Cohorts for Heart and Aging Research in Genomic Epidemiology Consortium (CHARGE), Genetic and Environmental Risk in AD/Defining Genetic, P. A. E. R. F. A. D. C. (., Grenier-Boley, B., Sims, R., Bis, J. C., Damotte, V., Naj, A. C., et al. (2019) · Nature Genetics · doi:10.1038/s41588-019-0358-2 · Cited by 2,946
Self-citationPericytes regulate the blood–brain barrier
Armulik, A., Genové, G., Mäe, M., Nisancioglu, M. H., Wallgard, E., Niaudet, C., He, L., Norlin, J., Lindblom, P., Strittmatter, K., et al. (2010) · Nature · doi:10.1038/nature09522 · Cited by 2,843
Non-motor symptoms of Parkinson's disease: diagnosis and management
Chaudhuri, K. R., Healy, D. G., & Schapira, A. H. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70373-8 · Cited by 2,807
Walker, F. O. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60111-1 · Cited by 2,603
Kiernan, M. C., Vucic, S., Cheah, B. C., Turner, M. R., Eisen, A., Hardiman, O., Burrell, J. R., & Zoing, M. C. (2011) · The Lancet · doi:10.1016/s0140-6736(10)61156-7 · Cited by 2,603
Development, maintenance and disruption of the blood-brain barrier
Obermeier, B., Daneman, R., & Ransohoff, R. M. (2013) · Nature Medicine · doi:10.1038/nm.3407 · Cited by 2,452
The blood–brain barrier: an overview
Ballabh, P., Braun, A., & Nedergaard, M. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2003.12.016 · Cited by 2,261
Nanoparticle Size and Surface Chemistry Determine Serum Protein Adsorption and Macrophage Uptake
Walkey, C. D., Olsen, J. B., Guo, H., Emili, A., & Chan, W. C. W. (2012) · Journal of the American Chemical Society · doi:10.1021/ja2084338 · Cited by 1,926
Bates, G. P., Dorsey, R., Gusella, J. F., Hayden, M. R., Kay, C., Leavitt, B. R., Nance, M., Ross, C. A., Scahill, R. I., Wetzel, R., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.5 · Cited by 1,641
The roles of intracellular protein-degradation pathways in neurodegeneration
Rubinsztein, D. C. (2006) · Nature · doi:10.1038/nature05291 · Cited by 1,625
Saraiva, C., Praça, C., Ferreira, R., Santos, T., Ferreira, L., & Bernardino, L. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.05.044 · Cited by 1,609
Pharmacological Treatment of Parkinson Disease: A Review
Connolly, B. S., & Lang, A. E. (2014) · JAMA · doi:10.1001/jama.2014.3654 · Cited by 1,498
Zhuang, X., Xiang, X., Grizzle, W., Sun, D., Zhang, S., Axtell, R. C., Ju, S., Mu, J., Zhang, L., Steinman, L., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2011.164 · Cited by 1,356
Toxic Proteins in Neurodegenerative Disease
Taylor, J. P., Hardy, J., & Fischbeck, K. H. (2002) · Science · doi:10.1126/science.1067122 · Cited by 1,251
Donepezil for dementia due to Alzheimer’s disease.
Birks, J. S., & Harvey, R. J. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001190.pub3 · Cited by 1,200
Huntington's disease: a clinical review
McColgan, P., & Tabrizi, S. J. (2018) · European Journal of Neurology · doi:10.1111/ene.13413 · Cited by 1,089
Huntington disease: natural history, biomarkers and prospects for therapeutics
Ross, C. A., Aylward, E. H., Wild, E. J., Langbehn, D. R., Long, J. D., Warner, J. H., Scahill, R. I., Leavitt, B. R., Stout, J. C., Paulsen, J. S., et al. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.24 · Cited by 1,016
Current and Future Treatments in Alzheimer Disease: An Update
Yiannopoulou, K. G., & Papageorgiou, S. G. (2020) · Journal of Central Nervous System Disease · doi:10.1177/1179573520907397 · Cited by 966
Xue, J., Zhao, Z., Zhang, L., Xue, L., Shen, S., Wen, Y., Wei, Z., Wang, L., Kong, L., Sun, H., et al. (2017) · Nature Nanotechnology · doi:10.1038/nnano.2017.54 · Cited by 959
Devinsky, O., Vezzani, A., O'Brien, T. J., Jette, N., Scheffer, I. E., de Curtis, M., & Perucca, P. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2018.24 · Cited by 959
Current Strategies for Brain Drug Delivery
Dong, X. (2018) · Theranostics · doi:10.7150/thno.21254 · Cited by 954
Ageing and Parkinson's disease: Why is advancing age the biggest risk factor?
Reeve, A., Simcox, E., & Turnbull, D. (2014) · Ageing Research Reviews · doi:10.1016/j.arr.2014.01.004 · Cited by 947
Oxidative stress, mitochondrial dysfunction and neurodegenerative diseases; a mechanistic insight
Bhat, A. H., Dar, K. B., Anees, S., Zargar, M. A., Masood, A., Sofi, M. A., & Ganie, S. A. (2015) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2015.07.025 · Cited by 928
Neuroinflammatory pathways as treatment targets and biomarkers in epilepsy
Vezzani, A., Balosso, S., & Ravizza, T. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0217-x · Cited by 893
Neurodegenerative Diseases and Prions
Prusiner, S. B. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105173442006 · Cited by 772
Brain metabolism in health, aging, and neurodegeneration
Camandola, S., & Mattson, M. P. (2017) · The EMBO Journal · doi:10.15252/embj.201695810 · Cited by 752
Kojima, R., Bojar, D., Rizzi, G., Hamri, G. C.-E., El-Baba, M. D., Saxena, P., Ausländer, S., Tan, K. R., & Fussenegger, M. (2018) · Nature Communications · doi:10.1038/s41467-018-03733-8 · Cited by 748
Chang, B. S., & Lowenstein, D. H. (2003) · New England Journal of Medicine · doi:10.1056/nejmra022308 · Cited by 731
Transport of drugs across the blood–brain barrier by nanoparticles.
Wohlfart, S., Gelperina, S., & Kreuter, J. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.08.017 · Cited by 715
Overcoming the Blood–Brain Barrier: The Role of Nanomaterials in Treating Neurological Diseases
Furtado, D., Björnmalm, M., Ayton, S., Bush, A. I., Kempe, K., & Caruso, F. (2018) · Advanced Materials · doi:10.1002/adma.201801362 · Cited by 708
Do Van, B., Gouel, F., Jonneaux, A., Timmerman, K., Gelé, P., Pétrault, M., Bastide, M., Laloux, C., Moreau, C., Bordet, R., et al. (2016) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.05.011 · Cited by 689
New avenues for anti-epileptic drug discovery and development
Löscher, W., Klitgaard, H., Twyman, R. E., & Schmidt, D. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4126 · Cited by 675
Protein misfolding in neurodegenerative diseases: Implications and strategies
Sweeney, P., Park, H., Baumann, M., Dunlop, J., Frydman, J., Kopito, R., McCampbell, A., Leblanc, G., Venkateswaran, A., Nurmi, A., et al. (2017) · Translational Neurodegeneration · doi:10.1186/s40035-017-0077-5 · Cited by 675
Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease
Korth, C., May, B. C. H., Cohen, F. E., & Prusiner, S. B. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.161274798 · Cited by 673
Mitochondria-Targeting Ceria Nanoparticles as Antioxidants for Alzheimer’s Disease
Kwon, H. J., Cha, M.-Y., Kim, D., Kim, D. K., Soh, M., Shin, K., Hyeon, T., & Mook-Jung, I. (2016) · ACS Nano · doi:10.1021/acsnano.5b08045 · Cited by 655
DNA damage and its links to neurodegeneration
Madabhushi, R., Pan, L., & Tsai, L.-H. (2014) · Neuron · doi:10.1016/j.neuron.2014.06.034 · Cited by 654
Nance, E. A., Woodworth, G. F., Sailor, K. A., Shih, T.-Y., Xu, Q., Swaminathan, G., Xiang, D., Eberhart, C., & Hanes, J. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003594 · Cited by 649
Neuroinflammation in amyotrophic lateral sclerosis: role of glial activation in motor neuron disease
Philips, T., & Robberecht, W. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70015-1 · Cited by 646
Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles
Singh, A. P., Biswas, A., Shukla, A., & Maiti, P. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0068-3 · Cited by 645
Cell death in the nervous system
Bredesen, D. E., Rao, R. V., & Mehlen, P. (2006) · Nature · doi:10.1038/nature05293 · Cited by 636
Alzheimer’s disease hypothesis and related therapies
Du, X., Wang, X., & Geng, M. (2018) · Translational Neurodegeneration · doi:10.1186/s40035-018-0107-y · Cited by 607
Animal models of neurodegenerative diseases
Dawson, T. M., Golde, T. E., & Lagier-Tourenne, C. (2018) · Nature Neuroscience · doi:10.1038/s41593-018-0236-8 · Cited by 576
Blood-brain barrier drug targeting: the future of brain drug development.
Pardridge, W. M. (2003) · Molecular Interventions · doi:10.1124/mi.3.2.90 · Cited by 570
Mittal, G., Sahana, D. K., Bhardwaj, V., & Ravi Kumar, M. N. V. (2007) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.01.016 · Cited by 551
Inhibition of Amyloid β Protein Fibrillation by Polymeric Nanoparticles
Cabaleiro-Lago, C., Quinlan-Pluck, F., Lynch, I., Lindman, S., Minogue, A. M., Thulin, E., Walsh, D. M., Dawson, K. A., & Linse, S. (2008) · Journal of the American Chemical Society · doi:10.1021/ja8041806 · Cited by 546
Dopamine-loaded blood exosomes targeted to brain for better treatment of Parkinson’s disease
Qu, M., Lin, Q., Huang, L., Fu, Y., Wang, L., He, S., Fu, Y., Yang, S., Zhang, Z., Zhang, L., et al. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.08.035 · Cited by 543
Exosomes for targeted siRNA delivery across biological barriers
EL Andaloussi, S., Lakhal, S., Mäger, I., & Wood, M. J. A. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.08.008 · Cited by 539
Tapeinos, C., Battaglini, M., & Ciofani, G. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.08.033 · Cited by 539
Energy metabolism in amyotrophic lateral sclerosis
Dupuis, L., Pradat, P.-F., Ludolph, A. C., & Loeffler, J.-P. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70224-6 · Cited by 537
Alexander, G. E. (2004) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2004.6.3/galexander · Cited by 523
Failure of the ubiquitin-proteasome system in Parkinson’s disease
McNaught, K. S. P., Olanow, C. W., Halliwell, B., Isacson, O., & Jenner, P. (2001) · Nature Reviews Neuroscience · doi:10.1038/35086067 · Cited by 519
Brain Endothelial Cell-Cell Junctions: How to “Open” the Blood Brain Barrier
Stamatovic, S., Keep, R., & Andjelkovic, A. (2008) · Current Neuropharmacology · doi:10.2174/157015908785777210 · Cited by 513
Systemic exosomal siRNA delivery reduced alpha‐synuclein aggregates in brains of transgenic mice
Cooper, J. M., Wiklander, P. B. O., Nordin, J. Z., Al‐Shawi, R., Wood, M. J., Vithlani, M., Schapira, A. H. V., Simons, J. P., El‐Andaloussi, S., & Alvarez‐Erviti, L. (2014) · Movement Disorders · doi:10.1002/mds.25978 · Cited by 507
Trajectory of Cognitive Decline After Incident Stroke
Levine, D. A., Galecki, A. T., Langa, K. M., Unverzagt, F. W., Kabeto, M. U., Giordani, B., & Wadley, V. G. (2015) · JAMA · doi:10.1001/jama.2015.6968 · Cited by 497
Nanoparticles evading the reticuloendothelial system: Role of the supported bilayer
Li, S.-D., & Huang, L. (2009) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2009.06.022 · Cited by 486
Transcytosis to Cross the Blood Brain Barrier, New Advancements and Challenges
Pulgar, V. M. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.01019 · Cited by 482
The History of Parkinson's Disease: Early Clinical Descriptions and Neurological Therapies
Goetz, C. G. (2011) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a008862 · Cited by 470
Calzoni, E., Cesaretti, A., Polchi, A., Di Michele, A., Tancini, B., & Emiliani, C. (2019) · Journal of Functional Biomaterials · doi:10.3390/jfb10010004 · Cited by 468
Ferroptosis and Its Role in Diverse Brain Diseases
Weiland, A., Wang, Y., Wu, W., Lan, X., Han, X., Li, Q., & Wang, J. (2019) · Molecular Neurobiology · doi:10.1007/s12035-018-1403-3 · Cited by 467
8-Hydroxyquinolines: a review of their metal chelating properties and medicinal applications
Prachayasittikul, V., Prachayasittikul, V., Prachayasittikul, S., & Ruchirawat, S. (2013) · Drug Design, Development and Therapy · doi:10.2147/dddt.s49763 · Cited by 445
Aryal, M., Arvanitis, C. D., Alexander, P. M., & McDannold, N. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.01.008 · Cited by 443
DNA Damage, DNA Repair, Aging, and Neurodegeneration
Maynard, S., Fang, E. F., Scheibye-Knudsen, M., Croteau, D. L., & Bohr, V. A. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a025130 · Cited by 438
An, F.-F., & Zhang, X.-H. (2017) · Theranostics · doi:10.7150/thno.19365 · Cited by 436
Modeling amyloid beta and tau pathology in human cerebral organoids
Gonzalez, C., Armijo, E., Bravo-Alegria, J., Becerra-Calixto, A., Mays, C. E., & Soto, C. (2018) · Molecular Psychiatry · doi:10.1038/s41380-018-0229-8 · Cited by 430
Kirik, D., Rosenblad, C., Björklund, A., & Mandel, R. J. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-12-04686.2000 · Cited by 428
Vieira, D., & Gamarra, L. (2016) · International Journal of Nanomedicine · doi:10.2147/ijn.s117210 · Cited by 427
Targeting Nrf2 to Suppress Ferroptosis and Mitochondrial Dysfunction in Neurodegeneration
Abdalkader, M., Lampinen, R., Kanninen, K. M., Malm, T. M., & Liddell, J. R. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00466 · Cited by 423
Zhang, L., Li, J., Tian, D., Sun, L., Wang, X., & Tian, M. (2020) · Cell Death & Disease · doi:10.1038/s41419-019-2182-0 · Cited by 413
Progress in brain targeting drug delivery system by nasal route
Khan, A. R., Liu, M., Khan, M. W., & Zhai, G. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.09.001 · Cited by 402
Long, Q., Upadhya, D., Hattiangady, B., Kim, D.-K., An, S. Y., Shuai, B., Prockop, D. J., & Shetty, A. K. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1703920114 · Cited by 401
Targeting Receptor-Mediated Transport for Delivery of Biologics Across the Blood-Brain Barrier
Lajoie, J. M., & Shusta, E. V. (2015) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010814-124852 · Cited by 399
Evolving Drug Delivery Strategies to Overcome the Blood Brain Barrier
S. Hersh, D., S. Wadajkar, A., B. Roberts, N., G. Perez, J., P. Connolly, N., Frenkel, V., A. Winkles, J., F. Woodworth, G., & J. Kim, A. (2016) · Current Pharmaceutical Design · doi:10.2174/1381612822666151221150733 · Cited by 387
Neutrophil‐Based Drug Delivery Systems
Chu, D., Dong, X., Shi, X., Zhang, C., & Wang, Z. (2018) · Advanced Materials · doi:10.1002/adma.201706245 · Cited by 386
Targeting the transferrin receptor for brain drug delivery
Johnsen, K. B., Burkhart, A., Thomsen, L. B., Andresen, T. L., & Moos, T. (2019) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2019.101665 · Cited by 370
Wilson, B., Samanta, M. K., Santhi, K., Kumar, K. P. S., Paramakrishnan, N., & Suresh, B. (2008) · Brain Research · doi:10.1016/j.brainres.2008.01.039 · Cited by 363
Neurodegenerative Diseases: Expanding the Prion Concept
Walker, L. C., & Jucker, M. (2015) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-071714-033828 · Cited by 361
Mahmoudi, M., Laurent, S., Shokrgozar, M. A., & Hosseinkhani, M. (2011) · ACS Nano · doi:10.1021/nn2021088 · Cited by 349
Designing super selectivity in multivalent nano-particle binding
Martinez-Veracoechea, F. J., & Frenkel, D. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1105351108 · Cited by 346
Current approaches to the treatment of Parkinson’s disease
Jankovic, J. (2008) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s2006 · Cited by 342
Blood–Brain Barrier Pathology in Alzheimer's and Parkinson's Disease: Implications for Drug Therapy
Desai, B. S., Monahan, A. J., Carvey, P. M., & Hendey, B. (2007) · Cell Transplantation · doi:10.3727/000000007783464731 · Cited by 339
Cano, A., Ettcheto, M., Chang, J.-H., Barroso, E., Espina, M., Kühne, B. A., Barenys, M., Auladell, C., Folch, J., Souto, E. B., et al. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.03.010 · Cited by 337
Wang, H., Sui, H., Zheng, Y., Jiang, Y., Shi, Y., Liang, J., & Zhao, L. (2019) · Nanoscale · doi:10.1039/c9nr01255a · Cited by 324
Suhr, O. B., Coelho, T., Buades, J., Pouget, J., Conceicao, I., Berk, J., Schmidt, H., Waddington-Cruz, M., Campistol, J. M., Bettencourt, B. R., et al. (2015) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-015-0326-6 · Cited by 321
Microglial Response to Gold Nanoparticles
Hutter, E., Boridy, S., Labrecque, S., Lalancette-Hébert, M., Kriz, J., Winnik, F. M., & Maysinger, D. (2010) · ACS Nano · doi:10.1021/nn901869f · Cited by 320
Membrane Curvature Induction and Tubulation Are Common Features of Synucleins and Apolipoproteins
Varkey, J., Isas, J. M., Mizuno, N., Jensen, M. B., Bhatia, V. K., Jao, C. C., Petrlova, J., Voss, J. C., Stamou, D. G., Steven, A. C., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.139576 · Cited by 319
Preparation of estradiol chitosan nanoparticles for improving nasal absorption and brain targeting
Wang, X., Chi, N., & Tang, X. (2008) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2008.07.005 · Cited by 305
Blood-Brain Delivery Methods Using Nanotechnology
Teleanu, D. M., Chircov, C., Grumezescu, A. M., Volceanov, A., & Teleanu, R. I. (2018) · Pharmaceutics · doi:10.3390/pharmaceutics10040269 · Cited by 305
Khongkow, M., Yata, T., Boonrungsiman, S., Ruktanonchai, U. R., Graham, D., & Namdee, K. (2019) · Scientific Reports · doi:10.1038/s41598-019-44569-6 · Cited by 303
Therapies targeting DNA and RNA in Huntington's disease
Wild, E. J., & Tabrizi, S. J. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30280-6 · Cited by 298
He, Q., Liu, J., Liang, J., Liu, X., Li, W., Liu, Z., Ding, Z., & Tuo, D. (2018) · Cells · doi:10.3390/cells7040024 · Cited by 298
The hidden genetics of epilepsy—a clinically important new paradigm
Thomas, R. H., & Berkovic, S. F. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.62 · Cited by 297
Nanoparticles and Neurotoxicity
Win-Shwe, T.-T., & Fujimaki, H. (2011) · International Journal of Molecular Sciences · doi:10.3390/ijms12096267 · Cited by 296
Nanotechnologies for Alzheimer's disease: diagnosis, therapy, and safety issues
Brambilla, D., Le Droumaguet, B., Nicolas, J., Hashemi, S. H., Wu, L.-P., Moghimi, S. M., Couvreur, P., & Andrieux, K. (2011) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2011.03.008 · Cited by 294
Drouin‐Ouellet, J., Sawiak, S. J., Cisbani, G., Lagacé, M., Kuan, W., Saint‐Pierre, M., Dury, R. J., Alata, W., St‐Amour, I., Mason, S. L., et al. (2015) · Annals of Neurology · doi:10.1002/ana.24406 · Cited by 288
Blood–brain-barrier organoids for investigating the permeability of CNS therapeutics
Bergmann, S., Lawler, S. E., Qu, Y., Fadzen, C. M., Wolfe, J. M., Regan, M. S., Pentelute, B. L., Agar, N. Y. R., & Cho, C.-F. (2018) · Nature Protocols · doi:10.1038/s41596-018-0066-x · Cited by 285
Clark, A. J., & Davis, M. E. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1517048112 · Cited by 280
Tau-Targeted Multifunctional Nanocomposite for Combinational Therapy of Alzheimer’s Disease
Chen, Q., Du, Y., Zhang, K., Liang, Z., Li, J., Yu, H., Ren, R., Feng, J., Jin, Z., Li, F., et al. (2018) · ACS Nano · doi:10.1021/acsnano.7b07625 · Cited by 280
Dube, A., Nicolazzo, J. A., & Larson, I. (2010) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2010.06.010 · Cited by 279
Matsumoto, J., Stewart, T., Sheng, L., Li, N., Bullock, K., Song, N., Shi, M., Banks, W. A., & Zhang, J. (2017) · Acta Neuropathologica Communications · doi:10.1186/s40478-017-0470-4 · Cited by 279
WILSON, B., SAMANTA, M., SANTHI, K., KUMAR, K., PARAMAKRISHNAN, N., & SURESH, B. (2008) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2008.03.009 · Cited by 278
Permanent inactivation of Huntington's disease mutation by personalized allele-specific CRISPR/Cas9
Shin, J. W., Kim, K.-H., Chao, M. J., Atwal, R. S., Gillis, T., MacDonald, M. E., Gusella, J. F., & Lee, J.-M. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw286 · Cited by 276
Dual Effect of Amino Modified Polystyrene Nanoparticles on Amyloid β Protein Fibrillation
Cabaleiro-Lago, C., Quinlan-Pluck, F., Lynch, I., Dawson, K. A., & Linse, S. (2010) · ACS Chemical Neuroscience · doi:10.1021/cn900027u · Cited by 275
Nanoemulsions for “Nose-to-Brain” Drug Delivery
Bonferoni, M. C., Rossi, S., Sandri, G., Ferrari, F., Gavini, E., Rassu, G., & Giunchedi, P. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11020084 · Cited by 269
Safety and efficacy of quinacrine in human prion disease (PRION-1 study): a patient-preference trial
Collinge, J., Gorham, M., Hudson, F., Kennedy, A., Keogh, G., Pal, S., Rossor, M., Rudge, P., Siddique, D., Spyer, M., et al. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70049-3 · Cited by 262
Hu, K., Shi, Y., Jiang, W., Han, J., Huang, S., & Jiang, X. (2011) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2011.05.062 · Cited by 261
The second brain and Parkinson’s disease
Lebouvier, T., Chaumette, T., Paillusson, S., Duyckaerts, C., Bruley des Varannes, S., Neunlist, M., & Derkinderen, P. (2009) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2009.06873.x · Cited by 261
Pahuja, R., Seth, K., Shukla, A., Shukla, R. K., Bhatnagar, P., Chauhan, L. K. S., Saxena, P. N., Arun, J., Chaudhari, B. P., Patel, D. K., et al. (2015) · ACS Nano · doi:10.1021/nn506408v · Cited by 260
Riluzole, Neuroprotection and Amyotrophic Lateral Sclerosis
Cheah, B. C., Vucic, S., Krishnan, A., & Kiernan, M. C. (2010) · Current Medicinal Chemistry · doi:10.2174/092986710791163939 · Cited by 258
Shaping nano-/micro-particles for enhanced vascular interaction in laminar flows
Lee, S.-Y., Ferrari, M., & Decuzzi, P. (2009) · Nanotechnology · doi:10.1088/0957-4484/20/49/495101 · Cited by 257
Blood-brain barrier transport machineries and targeted therapy of brain diseases
Barar, J., Rafi, M. A., Pourseif, M. M., & Omidi, Y. (2016) · BioImpacts · doi:10.15171/bi.2016.30 · Cited by 257
Misfolded protein aggregates: Mechanisms, structures and potential for disease transmission
Moreno-Gonzalez, I., & Soto, C. (2011) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2011.04.002 · Cited by 252
Neely, A., Perry, C., Varisli, B., Singh, A. K., Arbneshi, T., Senapati, D., Kalluri, J. R., & Ray, P. C. (2009) · ACS Nano · doi:10.1021/nn900813b · Cited by 244
Chitosan nanoparticles as a new delivery system for the anti-Alzheimer drug tacrine
Wilson, B., Samanta, M. K., Santhi, K., Kumar, K. P. S., Ramasamy, M., & Suresh, B. (2010) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2009.04.001 · Cited by 244
Adenosine kinase, epilepsy and stroke: mechanisms and therapies
Boison, D. (2006) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2006.10.008 · Cited by 241
Characterization and evaluation of chitosan nanoparticles for dopamine brain delivery
Trapani, A., De Giglio, E., Cafagna, D., Denora, N., Agrimi, G., Cassano, T., Gaetani, S., Cuomo, V., & Trapani, G. (2011) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2011.07.036 · Cited by 238
Selective Neuronal Loss in Ischemic Stroke and Cerebrovascular Disease
Baron, J.-C., Yamauchi, H., Fujioka, M., & Endres, M. (2014) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2013.188 · Cited by 236
Curcumin-decorated nanoliposomes with very high affinity for amyloid-β1-42 peptide
Mourtas, S., Canovi, M., Zona, C., Aurilia, D., Niarakis, A., La Ferla, B., Salmona, M., Nicotra, F., Gobbi, M., & Antimisiaris, S. G. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2010.10.027 · Cited by 230
Dietary Iron Oxide Nanoparticles Delay Aging and Ameliorate Neurodegeneration in Drosophila
Zhang, Y., Wang, Z., Li, X., Wang, L., Yin, M., Wang, L., Chen, N., Fan, C., & Song, H. (2016) · Advanced Materials · doi:10.1002/adma.201503893 · Cited by 224
Neurotherapeutic applications of nanoparticles in Alzheimer’s disease
Sahni, J. K., Doggui, S., Ali, J., Baboota, S., Dao, L., & Ramassamy, C. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.11.033 · Cited by 219
You, L., Wang, J., Liu, T., Zhang, Y., Han, X., Wang, T., Guo, S., Dong, T., Xu, J., Anderson, G. J., et al. (2018) · ACS Nano · doi:10.1021/acsnano.7b08172 · Cited by 219
Environmental Exposures and Parkinson’s Disease
Nandipati, S., & Litvan, I. (2016) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph13090881 · Cited by 218
Liu, Z., Jiang, M., Kang, T., Miao, D., Gu, G., Song, Q., Yao, L., Hu, Q., Tu, Y., Pang, Z., et al. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.02.003 · Cited by 217
Trimethylated chitosan-conjugated PLGA nanoparticles for the delivery of drugs to the brain
Wang, Z. H., Wang, Z. Y., Sun, C. S., Wang, C. Y., Jiang, T. Y., & Wang, S. L. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2009.09.104 · Cited by 214
Review of Current Strategies for Delivering Alzheimer’s Disease Drugs across the Blood-Brain Barrier
Wong, K. H., Riaz, M. K., Xie, Y., Zhang, X., Liu, Q., Chen, H., Bian, Z., Chen, X., Lu, A., & Yang, Z. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20020381 · Cited by 213
Zhang, J., Zhang, Y., Xing, S., Liang, Z., & Zeng, J. (2012) · Stroke · doi:10.1161/strokeaha.111.632448 · Cited by 211
Nose-to-brain delivery of lipid-based nanosystems for epileptic seizures and anxiety crisis
Costa, C., Moreira, J. N., Amaral, M. H., Sousa Lobo, J. M., & Silva, A. C. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.12.049 · Cited by 210
Gao, X., Wu, B., Zhang, Q., Chen, J., Zhu, J., Zhang, W., Rong, Z., Chen, H., & Jiang, X. (2007) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.05.026 · Cited by 207
The cytoplasmic plaque of tight junctions: A scaffolding and signalling center
Guillemot, L., Paschoud, S., Pulimeno, P., Foglia, A., & Citi, S. (2008) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2007.09.032 · Cited by 207
Efficacy of flupirtine on cognitive function in patients with CJD: A double-blind study
Otto, M., Cepek, L., Ratzka, P., Doehlinger, S., Boekhoff, I., Wiltfang, J., Irle, E., Pergande, G., Ellers-Lenz, B., Windl, O., et al. (2004) · Neurology · doi:10.1212/01.wnl.0000113764.35026.ef · Cited by 207
Systemic Exosomal Delivery of shRNA Minicircles Prevents Parkinsonian Pathology
Izco, M., Blesa, J., Schleef, M., Schmeer, M., Porcari, R., Al-Shawi, R., Ellmerich, S., de Toro, M., Gardiner, C., Seow, Y., et al. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.08.010 · Cited by 206
Sandhir, R., Yadav, A., Mehrotra, A., Sunkaria, A., Singh, A., & Sharma, S. (2014) · NeuroMolecular Medicine · doi:10.1007/s12017-013-8261-y · Cited by 204
CUI, Z., LOCKMAN, P., ATWOOD, C., HSU, C., GUPTE, A., ALLEN, D., & MUMPER, R. (2005) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2004.07.009 · Cited by 200
Cause of neural death in neurodegenerative diseases attributable to expansion of glutamine repeats
Perutz, M. F., & Windle, A. H. (2001) · Nature · doi:10.1038/35084141 · Cited by 199
Liposome delivery systems for the treatment of Alzheimer’s disease
Ross, C., Taylor, M., Fullwood, N., & Allsop, D. (2018) · International Journal of Nanomedicine · doi:10.2147/ijn.s183117 · Cited by 198
Resveratrol-loaded polymeric micelles protect cells from Aβ-induced oxidative stress
Lu, X., Ji, C., Xu, H., Li, X., Ding, H., Ye, M., Zhu, Z., Ding, D., Jiang, X., Ding, X., et al. (2009) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2009.03.021 · Cited by 190
Niu, X., Chen, J., & Gao, J. (2019) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2018.09.005 · Cited by 190
Inhibition of amyloid beta toxicity in zebrafish with a chaperone-gold nanoparticle dual strategy
Javed, I., Peng, G., Xing, Y., Yu, T., Zhao, M., Kakinen, A., Faridi, A., Parish, C. L., Ding, F., Davis, T. P., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11762-0 · Cited by 187
Drug delivery to the brain in Alzheimer's disease: Consideration of the blood–brain barrier
Banks, W. A. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.12.005 · Cited by 184
Barbara, R., Belletti, D., Pederzoli, F., Masoni, M., Keller, J., Ballestrazzi, A., Vandelli, M. A., Tosi, G., & Grabrucker, A. M. (2017) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2017.05.015 · Cited by 180
Liu, G., Men, P., Harris, P. L. R., Rolston, R. K., Perry, G., & Smith, M. A. (2006) · Neuroscience Letters · doi:10.1016/j.neulet.2006.07.020 · Cited by 178
Zhang, N., Yan, F., Liang, X., Wu, M., Shen, Y., Chen, M., Xu, Y., Zou, G., Jiang, P., Tang, C., et al. (2018) · Theranostics · doi:10.7150/thno.23734 · Cited by 178
Node Detection Using High-Dimensional Fuzzy Parcellation Applied to the Insular Cortex
Vercelli, U., Diano, M., Costa, T., Nani, A., Duca, S., Geminiani, G., Vercelli, A., & Cauda, F. (2016) · Neural Plasticity · doi:10.1155/2016/1938292 · Cited by 177
Spuch, C., & Navarro, C. (2011) · Journal of Drug Delivery · doi:10.1155/2011/469679 · Cited by 177
Gold‐Nanoparticle‐Based Multifunctional Amyloid‐β Inhibitor against Alzheimer’s Disease
Gao, N., Sun, H., Dong, K., Ren, J., & Qu, X. (2015) · Chemistry – A European Journal · doi:10.1002/chem.201404562 · Cited by 177
Advances in Parkinson’s Disease: 200 Years Later
del Rey, N. L., Quiroga‐Varela, A., Garbayo, E., Carballo‐Carbajal, I., Fernández‐Santiago, R., Monje, M. H. G., Trigo‐Damas, I., Blanco‐Prieto, M. J., & Blesa, J. (2018) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2018.00113 · Cited by 177
Gelain, F., Panseri, S., Antonini, S., Cunha, C., Donega, M., Lowery, J., Taraballi, F., Cerri, G., Montagna, M., Baldissera, F., et al. (2011) · ACS Nano · doi:10.1021/nn102461w · Cited by 175
Bondì, M. L., Craparo, E. F., Giammona, G., & Drago, F. (2010) · Nanomedicine · doi:10.2217/nnm.09.67 · Cited by 175
Carrier-mediated or specialized transport of drugs across the blood–brain barrier
Tsuji, A., & Tamai, I. (1999) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(98)00084-2 · Cited by 174
Iron Accumulates in Huntington’s Disease Neurons: Protection by Deferoxamine
Chen, J., Marks, E., Lai, B., Zhang, Z., Duce, J. A., Lam, L. Q., Volitakis, I., Bush, A. I., Hersch, S., & Fox, J. H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0077023 · Cited by 174
Neurotoxicity of Nanomaterials: An Up-to-Date Overview
Teleanu, D. M., Chircov, C., Grumezescu, A. M., & Teleanu, R. I. (2019) · Nanomaterials · doi:10.3390/nano9010096 · Cited by 170
Challenges Associated with Metal Chelation Therapy in Alzheimer's Disease
Hegde, M. L., Bharathi, P., Suram, A., Venugopal, C., Jagannathan, R., Poddar, P., Srinivas, P., Sambamurti, K., Rao, K. J., Scancar, J., et al. (2009) · Journal of Alzheimer's Disease · doi:10.3233/jad-2009-1068 · Cited by 167
Monomer-dependent secondary nucleation in amyloid formation
Linse, S. S. (2017) · Biophysical Reviews · doi:10.1007/s12551-017-0289-z · Cited by 166
Protein-Capped Metal Nanoparticles Inhibit Tau Aggregation in Alzheimer’s Disease
Sonawane, S. K., Ahmad, A., & Chinnathambi, S. (2019) · ACS Omega · doi:10.1021/acsomega.9b01411 · Cited by 166
Amantadine extended release for levodopa‐induced dyskinesia in Parkinson's disease (EASED Study)
Pahwa, R., Tanner, C. M., Hauser, R. A., Sethi, K. D., Isaacson, S., Truong, D. D., Struck, L. K., Ruby, A. E., McClure, N., Went, G. T., et al. (2015) · Movement Disorders · doi:10.1002/mds.26159 · Cited by 165
Selenium Nanoparticles as an Efficient Nanomedicine for the Therapy of Huntington’s Disease
Cong, W., Bai, R., Li, Y.-F., Wang, L., & Chen, C. (2019) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.9b12319 · Cited by 162
Theranostic applications of nanoparticles in neurodegenerative disorders
Ramanathan, S., Archunan, G., Sivakumar, M., Tamil Selvan, S., Fred, A. L., Kumar, S., Gulyás, B., & Padmanabhan, P. (2018) · International Journal of Nanomedicine · doi:10.2147/ijn.s149022 · Cited by 161
Kulkarni, P. V., Roney, C. A., Antich, P. P., Bonte, F. J., Raghu, A. V., & Aminabhavi, T. M. (2010) · WIREs Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.59 · Cited by 159
Bhatt, R., Singh, D., Prakash, A., & Mishra, N. (2015) · Drug Delivery · doi:10.3109/10717544.2014.880860 · Cited by 159
Yoo, J., Lee, E., Kim, H. Y., Youn, D., Jung, J., Kim, H., Chang, Y., Lee, W., Shin, J., Baek, S., et al. (2017) · Nature Nanotechnology · doi:10.1038/nnano.2017.133 · Cited by 159
International Review of Neurobiology
(2011) · International review of neurobiology · doi:10.1016/b978-0-12-385198-7.00014-x · Cited by 157
Hu, B., Dai, F., Fan, Z., Ma, G., Tang, Q., & Zhang, X. (2015) · Advanced Materials · doi:10.1002/adma.201502227 · Cited by 155
Picone, P., Bondi, M. L., Picone, P., Bondi, M. L., Montana, G., Bruno, A., Pitarresi, G., Giammona, G., & Di Carlo, M. (2009) · Free Radical Research · doi:10.1080/10715760903214454 · Cited by 151
Mead, B. P., Kim, N., Miller, G. W., Hodges, D., Mastorakos, P., Klibanov, A. L., Mandell, J. W., Hirsh, J., Suk, J. S., Hanes, J., et al. (2017) · Nano Letters · doi:10.1021/acs.nanolett.7b00616 · Cited by 151
Carradori, D., Balducci, C., Re, F., Brambilla, D., Droumaguet, B. L., Flores, O., Gaudin, A., Mura, S., Forloni, G., Ordóñez‐Gutiérrez, L., et al. (2017) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2017.12.006 · Cited by 150
Epilepsy Disease and Nose-to-Brain Delivery of Polymeric Nanoparticles: An Overview
Musumeci, T., Bonaccorso, A., & Puglisi, G. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11030118 · Cited by 149
Chitosan as a suitable nanocarrier material for anti-Alzheimer drug delivery
Sarvaiya, J., & Agrawal, Y. K. (2014) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2014.08.052 · Cited by 148
Liu, G., Men, P., Kudo, W., Perry, G., & Smith, M. A. (2009) · Neuroscience Letters · doi:10.1016/j.neulet.2009.03.064 · Cited by 148
Mulik, R. S., Mönkkönen, J., Juvonen, R. O., Mahadik, K. R., & Paradkar, A. R. (2010) · Molecular Pharmaceutics · doi:10.1021/mp900306x · Cited by 146
Superoxide Dismutase-Loaded PLGA Nanoparticles Protect Cultured Human Neurons Under Oxidative Stress
Reddy, M. K., Wu, L., Kou, W., Ghorpade, A., & Labhasetwar, V. D. (2008) · Applied Biochemistry and Biotechnology · doi:10.1007/s12010-008-8232-1 · Cited by 146
Qu, M., Lin, Q., He, S., Wang, L., Fu, Y. S., Zhang, Z., & Zhang, L. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.03.019 · Cited by 146
Sharma, R., Smits, I. P. M., la Vega, L. D., Lee, C., & Willerth, S. M. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.00057 · Cited by 146
Muthuraman, M., Koirala, N., Ciolac, D., Pintea, B., Glaser, M. B., Groppa, S. A., Tamás, G., & Groppa, S. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00711 · Cited by 144
Kashyap, K., & Shukla, R. (2019) · Current Drug Delivery · doi:10.2174/1567201816666191029122740 · Cited by 144
Exosomes in Parkinson’s Disease
Wu, X., Zheng, T., & Zhang, B. (2016) · Neuroscience Bulletin · doi:10.1007/s12264-016-0092-z · Cited by 143
Nanotechnology for Delivery of Drugs to the Brain for Epilepsy
Bennewitz, M. F., & Saltzman, W. M. (2009) · Neurotherapeutics · doi:10.1016/j.nurt.2009.01.018 · Cited by 142
Branched KLVFF Tetramers Strongly Potentiate Inhibition of β‐Amyloid Aggregation
Chafekar, S. M., Malda, H., Merkx, M., Meijer, E. W., Viertl, D., Lashuel, H. A., Baas, F., & Scheper, W. (2007) · ChemBioChem · doi:10.1002/cbic.200700338 · Cited by 141
Kirik, D., Georgievska, B., Burger, C., Winkler, C., Muzyczka, N., Mandel, R. J., & Björklund, A. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.062047599 · Cited by 140
Risk factors for incident dementia after stroke and transient ischemic attack
Yang, J., Wong, A., Wang, Z., Liu, W., Au, L., Xiong, Y., Chu, W. W. C., Leung, E. Y. L., Chen, S., Lau, C., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.01.003 · Cited by 137
CuII(atsm) inhibits ferroptosis: Implications for treatment of neurodegenerative disease
Southon, A., Szostak, K., Acevedo, K. M., Dent, K. A., Volitakis, I., Belaidi, A. A., Barnham, K. J., Crouch, P. J., Ayton, S., Donnelly, P. S., et al. (2020) · British Journal of Pharmacology · doi:10.1111/bph.14881 · Cited by 136
Azadi, A., Hamidi, M., & Rouini, M. R. (2013) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2013.10.004 · Cited by 134
Lohan, S., Raza, K., Mehta, S. K., Bhatti, G. K., Saini, S., & Singh, B. (2017) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2017.07.080 · Cited by 133
Ikeda, K., Okada, T., Sawada, S.-I., Akiyoshi, K., & Matsuzaki, K. (2006) · FEBS Letters · doi:10.1016/j.febslet.2006.11.009 · Cited by 132
Klajnert‐Maculewicz, B., Cortijo-Arellano, M., Bryszewska, M. J., & Cladera, J. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.11.053 · Cited by 132
Zhu, W., Masood, F., O'Brien, J. R., & Zhang, L. G. (2015) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2014.12.001 · Cited by 131
Adsorptive-Mediated Brain Delivery Systems
Lu, W. (2012) · Current Pharmaceutical Biotechnology · doi:10.2174/138920112803341851 · Cited by 129
Jamwal, S., & Kumar, P. (2019) · Current Neuropharmacology · doi:10.2174/1570159x16666180302115032 · Cited by 128
Delcroix, G. J.-R., Garbayo, E., Sindji, L., Thomas, O., Vanpouille‐Box, C., Schiller, P. C., & Montero‐Menei, C. N. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.10.041 · Cited by 127
da Rocha Lindner, G., Bonfanti Santos, D., Colle, D., Gasnhar Moreira, E. L., Daniel Prediger, R., Farina, M., Khalil, N. M., & Mara Mainardes, R. (2015) · Nanomedicine · doi:10.2217/nnm.14.165 · Cited by 126
Nogueira, M. H., Yasuda, C. L., Coan, A. C., Kanner, A. M., & Cendes, F. (2017) · Epilepsia · doi:10.1111/epi.13781 · Cited by 126
Sousa, F., Mandal, S., Garrovo, C., Astolfo, A., Bonifacio, A., Latawiec, D., Menk, R. H., Arfelli, F., Huewel, S., Legname, G., et al. (2010) · Nanoscale · doi:10.1039/c0nr00345j · Cited by 125
Rocha, S., Thünemann, A. F., Pereira, M. D. C., Coelho, M. A. N., Möhwald, H., & Brezesinski, G. (2008) · Biophysical Chemistry · doi:10.1016/j.bpc.2008.06.010 · Cited by 124
Imaging of Microglia Activation in Stroke
Thiel, A., & Heiss, W.-D. (2011) · Stroke · doi:10.1161/strokeaha.110.598821 · Cited by 124
Research works printed but not linked: 13
- Birks J. S., 2018, Cochrane Database Syst. Rev., 6, CD001190
- Carlesi C., 2011, Arch. Ital. Biol., 149, 151
- Chen W., 2018, Adv. Mater., 30
- Fu T., 2016, Neural Plast., 2016, 1
- Wang Y. L., 2018, Zhonghua Yixue Zazhi, 98, 2678
- Cummings J., 2017, J. Prev. Alzheimers Dis., 4, 109
- Hickey P., 2011, Drug Des., Dev. Ther., 5, 241
- Fernandez H. H., 2016, npj Parkinson's Dis., 2, 1
- 10.1002/adma.201801362 · DOI · Paper page
- Shin J. W., 2016, Hum. Mol. Genet., 25, 4566
- Sone D., 2019, Mol. Psychiatry
- Yusuf M., 2012, Int. J. Nanomed., 7, 4311
- Carpenter D. O., 2001, Int. J. Occup. Med. Environ. Health, 14, 209
Cited by
Lung cancer immunotherapy: progress, pitfalls, and promises
Lahiri, A., Maji, A., Potdar, P. D., Singh, N., Parikh, P., Bisht, B., Mukherjee, A., & Paul, M. K. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01740-y · Cited by 1,102
Self-citationOuyang, J., Xie, A., Zhou, J., Liu, R., Wang, L., Liu, H., Kong, N., & Tao, W. (2022) · Chemical Society Reviews · doi:10.1039/d1cs01148k · Cited by 385
Radiopharmaceuticals: navigating the frontier of precision medicine and therapeutic innovation
Dhoundiyal, S., Srivastava, S., Kumar, S., Singh, G., Ashique, S., Pal, R., Mishra, N., & Taghizadeh-Hesary, F. (2024) · European Journal of Medical Research · doi:10.1186/s40001-023-01627-0 · Cited by 144
“Using nano-carriers like liposomes, nanoparticles, and micelles, radiopharmaceuticals can be protected, ensuring their delicate contents remain intact, while also offering improved compatibility and extended circulation within the body [63].”
BackgroundLa Barbera, L., Mauri, E., D’Amelio, M., & Gori, M. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.939855 · Cited by 74
Moorthy, H., & Govindaraju, T. (2021) · ACS Applied Bio Materials · doi:10.1021/acsabm.0c01319 · Cited by 64
Metadata
- Authors
- Mukherjee, S., Madamsetty, V. S., Bhattacharya, D., Roy Chowdhury, S., Paul, M. K., & Mukherjee, A.
- Affiliations
- Rice University (US)
- Mayo Clinic (US)
- Birla Institute of Technology and Science, Pilani (IN)
- Department of Pharmaceutical Sciences College of Pharmacy University of Nebraska Medical Center 986025 Nebraska Medical Center Omaha NE 68198‐6025 USA
- University of California, Los Angeles (US)
- Aavishkar Oral Strips Pvt. Ltd. 109/3, IDA, Phase 2, Sector 2, Lane 6, Cherlapally Hyderabad Telangana 500051 India
- Corresponding author
- Mukherjee, Sudip
- Paul, Manash Kumar
- Mukherjee, Anubhab
- Venue
- Advanced Functional Materials
- Publisher
- Wiley
- Published
- 2020-06-16
- Volume
- 30
- Issue
- 35
- ISSN
- 1616-301X (ISSN-L)
- 1616-3028
- OpenAlex
- W3036302963
- Cited by
- 152
- References
- 373
- Citations by year
- 2026: 12 · 2025: 32 · 2024: 29 · 2023: 24 · 2022: 29 · 2021: 22 · 2020: 4
- FWCI
- 5.14
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Advanced Functional Materials (publishedVersion)
- Funders
- Rice University
- University of California, Los Angeles
- Mayo Clinic
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
- Keywords
- nanomedicine, neurodegenerative diseases, theranostics, blood-brain barrier, engineered nanoparticles, liposomes, polymeric nanoparticles, metal nanoparticles, bionanoparticles, Alzheimer's disease, Parkinson's disease, Huntington's disease, prion disease, amyotrophic lateral sclerosis, neuroprotection, nanoparticle toxicity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.